v3.22.2.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Cash flows from operating activities:    
Net loss $ (4,681,231) $ (4,699,034)
Stock-based compensation expense included in -    
General and administrative costs 1,160,649 1,854,058
Increase in -    
Advances on research and development contract services 3,224 (139,120)
Prepaid insurance 22,375 (31,012)
Other prepaid expenses and current assets (13,708) (17,224)
Accounts payable and accrued expenses 81,433 25,348
Research and development contract liabilities 23,969 10,918
Net cash used in operating activities (3,403,289) (2,996,066)
Cash flows from financing activities:    
Proceeds from sale of common stock in direct equity offering, net of offering costs 5,141,384 3,689,761
Exercise of common stock warrants 17,100
Exercise of common stock options 201,000
Payment of deferred offering costs (20,467)
Net cash provided by financing activities 5,141,384 3,887,394
Cash:    
Net increase 1,738,095 891,328
Balance at beginning of period 4,823,745 5,069,266
Balance at end of period 6,561,840 5,960,594
Supplemental disclosures of cash flow information:    
Interest 5,240 2,944
Income taxes
Non-cash investing and financing activities:    
Accrual of deferred offering costs $ 16,376

Source